Central Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Cancer

MalaCards integrated aliases for Central Nervous System Cancer:

Name: Central Nervous System Cancer 12 54 15 17
Malignant Neoplasm of Central Nervous System 12
Neoplasm of the Central Nervous System 6
Neoplasm of Central Nervous System 12
Central Nervous System Neoplasms 43
Central Nervous System Neoplasm 17
Central Nervous System Tumors 12
Central Nervous System Tumor 12
Malignant Tumor of Cns 12
Cns Neoplasm 12


External Ids:

Disease Ontology 12 DOID:3620
MeSH 43 D016543
NCIt 49 C4627 C9293
SNOMED-CT 67 126951006 372062007
ICD10 32 C72.9
UMLS 71 C0085136 C0348374

Summaries for Central Nervous System Cancer

Disease Ontology : 12 A nervous system cancer that is located in the central nervous system.

MalaCards based summary : Central Nervous System Cancer, also known as malignant neoplasm of central nervous system, is related to central nervous system benign neoplasm and central nervous system hematologic cancer. An important gene associated with Central Nervous System Cancer is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Magnesium Sulfate and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and t cells.

Related Diseases for Central Nervous System Cancer

Diseases related to Central Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 474)
# Related Disease Score Top Affiliating Genes
1 central nervous system benign neoplasm 33.5 SERPINA3 MIR34A MIR125B1 KDM4C H2AC18
2 central nervous system hematologic cancer 33.4 MIR199A1 MIR124-1 KDM4C
3 brain cancer 33.2 SMARCB1 SERPINA3 MIR9-1 MIR548B MIR21 MIR19A
4 meningioma, familial 32.2 SMARCB1 SERPINA3 MIR548B MIR34A MIR15B H2AC18
5 grade iii astrocytoma 31.8 SERPINA3 MIR196A1 MIR10A KDM4C H2AC18
6 rhabdoid cancer 31.8 SMARCB1 KDM4C H2AC18
7 secretory meningioma 31.6 SMARCB1 SERPINA3
8 fibrillary astrocytoma 31.4 SERPINA3 KDM4C H2AC18
9 leukemia, acute myeloid 31.3 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
10 leukemia, chronic myeloid 31.1 MIR9-1 MIR19A MIR199A1 MIR196A1 MIR17 MIR125A
11 demyelinating disease 31.0 SERPINA3 MIR9-1 MIR15B MIR155 MIR125A MIR124-1
12 in situ carcinoma 30.9 SERPINA3 MIR548B MIR17 H2AC18
13 glioma 30.9 MIR34A MIR21 MIR19A MIR17 MIR15B
14 leukemia, acute lymphoblastic 30.9 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
15 medulloblastoma 30.9 SMARCB1 MIR9-1 MIR34A MIR19A MIR17 MIR125A
16 esophageal cancer 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR155
17 brain glioma 30.8 MIR34A MIR10A KDM4C
18 lymphoma, non-hodgkin, familial 30.8 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
19 renal cell carcinoma, nonpapillary 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
20 placenta disease 30.8 SERPINA3 MIR199A1 H2AC18
21 leukemia, chronic lymphocytic 30.7 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1
22 pancreatic cancer 30.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
23 kidney cancer 30.6 MIR21 MIR199A1 MIR17 H2AC18
24 lung cancer 30.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
25 mismatch repair cancer syndrome 11.7
26 meningioma, radiation-induced 11.6
27 cellular ependymoma 11.6
28 neurilemmomatosis 11.6
29 subependymal giant cell astrocytoma 11.6
30 glioma susceptibility 2 11.3
31 glioma susceptibility 9 11.3
32 schwannomatosis 1 11.2
33 central nervous system primitive neuroectodermal neoplasm 11.2
34 diffuse midline glioma, h3 k27m-mutant 11.2
35 central nervous system sarcoma 11.2
36 cranial nerve neoplasm 11.2
37 central nervous system germ cell tumor 11.2
38 central nervous system melanocytic neoplasm 11.2
39 central nervous system mesenchymal non-meningothelial tumor 11.2
40 spinal cancer 11.2
41 chromosomal deletion syndrome 10.8 MIR9-1 MIR196A1 MIR17 MIR15B H2AC18
42 germ cell and embryonal cancer 10.8 SERPINA3 MIR9-1 KDM4C H2AC18
43 miyoshi muscular dystrophy 1 10.8 MIR34A MIR21 MIR155
44 muscle cancer 10.8 SMARCB1 SERPINA3 MIR9-1 MIR199A1 MIR196A1 H2AC18
45 esophagus adenocarcinoma 10.8 MIR21 MIR199A1 MIR196A1 MIR145
46 oropharynx cancer 10.8 SERPINA3 MIR9-1 MIR199A1 H2AC18
47 skeletal muscle cancer 10.8 SMARCB1 SERPINA3 MIR199A1 H2AC18
48 endocrine organ benign neoplasm 10.8 SERPINA3 MIR21 MIR199A1 KDM4C H2AC18
49 fetal alcohol spectrum disorder 10.8 MIR9-1 KDM4C H2AC18
50 cardiovascular organ benign neoplasm 10.8 SERPINA3 MIR10A KDM4C H2AC18

Graphical network of the top 20 diseases related to Central Nervous System Cancer:

Diseases related to Central Nervous System Cancer

Symptoms & Phenotypes for Central Nervous System Cancer

Drugs & Therapeutics for Central Nervous System Cancer

Drugs for Central Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 412)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
7 Orange Approved Phase 3
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
Cisatracurium Approved Phase 3 96946-41-7
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
Trioxsalen Approved Phase 3 3902-71-4 5585
Ondansetron Approved Phase 3 99614-02-5 4595
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ofloxacin Approved Phase 3 82419-36-1 4583
Thioguanine Approved Phase 3 154-42-7 2723601
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22 Mitolactol Investigational Phase 3 10318-26-0
23 Molgramostim Investigational Phase 3 99283-10-0
24 Anesthetics Phase 3
25 glucocorticoids Phase 3
26 Antihypertensive Agents Phase 3
27 Vasoconstrictor Agents Phase 3
28 Amoxicillin-Potassium Clavulanate Combination Phase 3
29 beta-Lactamase Inhibitors Phase 3
30 Dihematoporphyrin Ether Phase 3
31 Hematoporphyrins Phase 3
32 Hematoporphyrin Derivative Phase 3
33 Ether Phase 3
34 Liver Extracts Phase 3
35 Antiemetics Phase 3
36 Cytochrome P-450 Enzyme Inhibitors Phase 3
37 Emetics Phase 3
38 Analgesics, Opioid Phase 3
39 Neurotransmitter Agents Phase 3
40 Dopamine Agents Phase 3
41 Central Nervous System Stimulants Phase 3
42 Dexmethylphenidate Hydrochloride Phase 3
Ethanol Approved Phase 2 64-17-5 702
Nedaplatin Approved, Investigational Phase 2 95734-82-0
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
Chlorpheniramine Approved Phase 1, Phase 2 132-22-9, 113-92-8 2725
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
Aminolevulinic acid Approved Phase 2 106-60-5 137
Phenylacetic acid Approved Phase 2 103-82-2 999
Sodium citrate Approved, Investigational Phase 2 68-04-2

Interventional clinical trials:

(show top 50) (show all 635)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
4 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
8 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Unknown status NCT03558516 Phase 3 Magnesium group;Normal saline group
11 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
12 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
13 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
14 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
15 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
16 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
17 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
18 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
20 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
21 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
22 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
23 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
24 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
25 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
26 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
27 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
28 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
29 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
30 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
31 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
32 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
33 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
34 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
35 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
36 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
37 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
38 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
39 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
40 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
41 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
42 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
43 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
44 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
45 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
46 Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
47 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
48 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
49 Pediatric Low Grade Astrocytoma: Treatment Guidance Unknown status NCT00005084 Phase 2
50 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide

Search NIH Clinical Center for Central Nervous System Cancer

Cochrane evidence based reviews: central nervous system neoplasms

Genetic Tests for Central Nervous System Cancer

Anatomical Context for Central Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Cancer:

Central Nervous System

MalaCards organs/tissues related to Central Nervous System Cancer:

Brain, T Cells, Testes, Spinal Cord, Pituitary, Breast, Prostate

Publications for Central Nervous System Cancer

Articles related to Central Nervous System Cancer:

(show top 50) (show all 177)
# Title Authors PMID Year
Arylsulfatase A in serum from patients with cancer of various organs. 54 61
1687888 1991
[Arylsulfatase A--physico-chemical properties and the use of enzyme radioimmunoassay in medical diagnosis]. 61 54
1688265 1991
Locoregionally Delivered CAR T Cells Are Effective in CNS Cancer Models. 61
32385074 2020
Work Personality, Core Self-evaluation and Perceived Career Barriers in Young Adult Central Nervous System Cancer Survivors. 61
32399851 2020
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. 61
32459291 2020
[A Case of Primary Intracranial Malignant Melanoma Mimicking a Traumatic Brain Contusion]. 61
32312936 2020
Computational Modeling of Neuropsychological Test Performance to Disentangle Impaired Cognitive Processes in Cancer Patients. 61
32239149 2020
Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. 61
32004776 2020
Case-control study of brain and other central nervous system cancer among workers at semiconductor and storage device manufacturing facilities. 61
32019845 2020
Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. 61
32146576 2020
Donors With Central Nervous System Cancer: Proceed With Vigilance. 61
31596741 2020
Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. 61
31896490 2020
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. 61
32124043 2020
Advancing biology based therapeutic approaches for atypical teratoid rhabdoid tumors. 61
32129445 2020
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature. 61
32082673 2020
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancer. 61
31553925 2019
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 61
30585513 2019
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells. 61
31654739 2019
PD-L1/PD-1 Axis in Glioblastoma Multiforme. 61
31661771 2019
Bimodular Antiparallel G-Quadruplex Nanoconstruct with Antiproliferative Activity. 61
31597343 2019
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 61
31049790 2019
Age, cancer site and gender associations with symptoms and problems in specialised palliative care: a large, nationwide, register-based study. 61
31563863 2019
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 61
30395335 2019
Angiocentric glioma mimicking encephalomalacia. 61
30976372 2019
PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling. 61
32309805 2019
Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. 61
30825593 2019
Retrospective Exposure Assessment for Semiconductor and Storage Device Manufacturing Facilities. 61
30946698 2019
Fluorodeoxyglucose Detected Changes in Brain Metabolism After Chemotherapy in Pediatric Non-Hodgkin Lymphoma. 61
30630683 2019
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. 61
30350913 2019
Risk of Radiation-Induced Cancer From Computed Tomography Angiography Use in Imaging Surveillance for Unruptured Cerebral Aneurysms. 61
30580703 2018
Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients. 61
30264947 2018
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells. 61
30199037 2018
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. 61
29511029 2018
Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. 61
29427203 2018
Imaging Gliomas with Nanoparticle-Labeled Stem Cells. 61
29521296 2018
Outcomes of Organ Transplantation from Donors with a Cancer History. 61
29455213 2018
Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis. 61
30405856 2018
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 61
30140655 2018
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. 61
29374660 2018
Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature. 61
28775171 2017
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. 61
28426850 2017
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. 61
30034079 2017
Improving Functional Mobility in Children and Adolescents Undergoing Treatment for Non-Central Nervous System Cancers: A Systematic Review. 61
28942910 2017
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. 61
28497710 2017
Biomarkers and Immunotherapeutic Targets in Glioblastoma. 61
28300714 2017
The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required. 61
28440461 2017
Estimating the Proportion of Childhood Cancer Cases and Costs Attributable to the Environment in California. 61
28323471 2017
BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation. 61
27956254 2017
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. 61
29270434 2017
Atypical Teratoid/Rhabdoid Tumor of the Pineal Region in a Young Adult Male Patient: Case Report and Review of the Literature. 61
27144539 2017

Variations for Central Nervous System Cancer

ClinVar genetic disease variations for Central Nervous System Cancer:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SMARCB1 NM_003073.5(SMARCB1):c.351dup (p.Thr118fs)duplication Pathogenic 493002 rs1555876140 22:24135858-24135859 22:23793671-23793672

Expression for Central Nervous System Cancer

Search GEO for disease gene expression data for Central Nervous System Cancer.

Pathways for Central Nervous System Cancer

Pathways related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR17
2 11.61 MIR9-1 MIR21 MIR125B1 MIR125A MIR124-1 MIR10A
3 11.26 MIR19A MIR17 MIR10A
4 10.37 MIR199A1 MIR145

GO Terms for Central Nervous System Cancer

Cellular components related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 SERPINA3 MIR9-1 MIR21 MIR19A MIR155 MIR125A
2 extracellular space GO:0005615 9.7 SERPINA3 MIR21 MIR19A MIR199A1 MIR17 MIR15B
3 extracellular vesicle GO:1903561 9.17 MIR34A MIR21 MIR19A MIR17 MIR15B MIR125B1

Biological processes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.01 MIR34A MIR21 MIR155 MIR125A KDM4C
2 negative regulation of gene expression GO:0010629 9.89 MIR21 MIR17 MIR155 MIR125A MIR124-1
3 negative regulation of inflammatory response GO:0050728 9.83 MIR19A MIR155 MIR145 MIR124-1
4 cellular response to hypoxia GO:0071456 9.81 MIR34A MIR17 MIR155 MIR124-1
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.72 MIR199A1 MIR196A1 MIR155
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.71 MIR15B MIR155 MIR10A
7 negative regulation of angiogenesis GO:0016525 9.7 MIR34A MIR21 MIR15B MIR145 MIR125B1 MIR125A
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.67 MIR21 MIR19A MIR199A1 MIR145
9 negative regulation of innate immune response GO:0045824 9.65 MIR21 MIR155
10 negative regulation of JAK-STAT cascade GO:0046426 9.65 MIR9-1 MIR155
11 negative regulation of toll-like receptor signaling pathway GO:0034122 9.65 MIR19A MIR17
12 negative regulation of sprouting angiogenesis GO:1903671 9.65 MIR34A MIR19A MIR17
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.65 MIR34A MIR199A1 MIR17 MIR15B MIR125A
14 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.64 MIR17 MIR155
15 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.64 MIR19A MIR199A1
16 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.63 MIR125B1 MIR125A
17 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.63 MIR21 MIR125A
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.63 MIR199A1 MIR17 MIR155
19 negative regulation of matrix metallopeptidase secretion GO:1904465 9.62 MIR19A MIR199A1
20 negative regulation of microglial cell activation GO:1903979 9.62 MIR155 MIR124-1
21 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34A MIR199A1 MIR15B MIR155
22 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.61 MIR155 MIR125A
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR199A1 MIR17 MIR155
24 positive regulation of metalloendopeptidase activity GO:1904685 9.6 MIR21 MIR17
25 negative regulation of STAT cascade GO:1904893 9.59 MIR125B1 MIR125A
26 negative regulation of vascular wound healing GO:0061044 9.58 MIR34A MIR155
27 negative regulation of regulatory T cell differentiation GO:0045590 9.58 MIR21 MIR155
28 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.58 MIR21 MIR125B1 MIR124-1
29 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.57 MIR21 MIR17
30 negative regulation of histone H3-K9 trimethylation GO:1900113 9.56 SMARCB1 KDM4C
31 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR21 MIR17 MIR15B MIR155 MIR145
32 gene silencing by miRNA GO:0035195 9.47 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1

Molecular functions related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1
2 mRNA 3'-UTR binding GO:0003730 9.13 MIR21 MIR15B MIR125A

Sources for Central Nervous System Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....